FDA Calls for New Boxed Warning on All CAR-T Products Most serious warning would alert patients, providers on potential risk for secondary malignancies Jan 23, 2024
Daratumumab Added to Standard Therapy Improves PFS in Multiple Myeloma Subcutaneous administration of the anti-CD38 antibody also made for easier dosing Jan 04, 2024
Can JAK Inhibition Help Overcome Lenalidomide Resistance in Myeloma? Early-phase experience with ruxolitinib suggests potential role in relapsed/refractory disease Dec 21, 2023 video
Why Some Myeloma Patients Refuse Stem Cell Transplant Study shows the various factors behind refusal of autologous stem cell transplantation Dec 15, 2023 video
Four Drugs Top Three for Upfront Treatment of Multiple Myeloma Adding anti-CD38 antibodies boosts response and PFS, but timing, sequencing, cost questioned Dec 13, 2023
Benefits of Myeloma Regimens in the Real World Fall Well Short of Trials Survival 75% worse compared with outcomes seen in registrational studies Dec 10, 2023
Let's Talk Drug Prices; Restoring the Sense of Touch; Learning From Tumors in a Dish News, features, and commentary about cancer-related issues Dec 01, 2023
FDA Investigating 'Serious Risk' of Malignancy After CAR-T Therapy Applies to all approved therapies, but benefits still outweigh risks, agency says Nov 28, 2023
Vitamin D for Neuropathy; Good & Bad News for CAR-T; New Labeling for Surgical Mesh News, features, and commentary about cancer-related issues Nov 10, 2023
Wearables as Cancer Monitors; No China Price Break; Cancer Mystery in Appalachia News, features, and commentary about cancer-related issues Nov 03, 2023
Quad Regimen for High-Risk Myeloma Produces High Rates of Durable MRD Negativity Two-thirds of transplant-eligible patients met endpoint with isatuximab/KRd Oct 19, 2023
Lonely Cancer Deaths; Virtual Reality for Pain; 3D Models May Improve Treatment News, features, and commentary about cancer-related issues Oct 19, 2023
Chemo Shortage: 'Paycheck to Paycheck'; Cancer Blood Test Shines; Struggling to Live News, features, and commentary about cancer-related issues Oct 06, 2023
IV Immunoglobulin May Cut Infection Risk of Anti-BCMA Agents for Myeloma Small retrospective study finds fewer severe infections during periods of replacement therapy Sep 29, 2023
Cancer Drug Shortages for Kids; Pharma Agrees to Price Talks; Catch-Up on Screening News, features, and commentary about cancer-related issues Sep 28, 2023
Stem-Cell Mobilization Booster Wins FDA Approval for Multiple Myeloma Motixafortide plus filgrastim increased adequate harvest rate from 9.5% to 67.5% Sep 11, 2023
Microdevices for Glioma; Cervical Adenocarcinoma Test; Language Gaps and Cancer Care News, features, and commentary about cancer-related issues Sep 07, 2023
Novel Oral Tx Shows Early Promise in Relapsed/Refractory Myeloma Mezigdomide led to 41% response rate in heavily pretreated patients Aug 30, 2023
Nurse Suspected of Poisoning; Hospital Mask Mandates Return; Congressman's Cancer Dx Health news and commentary from around the Web gathered by ΒιΆΉ΄«Γ½ staff Aug 30, 2023
WHO Links Sweetener to Cancer; Younger-Age CRC Risk; PCOS and Ovarian Cancer News, features, and commentary about cancer-related issues Jun 29, 2023
New Agents for Relapsed/Refractory Myeloma Impress in Early-Stage Clinical Trials High rates of deep, durable response with bispecific antibody, rapidly produced CAR T-cell agents Jun 05, 2023
CAR-T Tops Standard Care in Heavily Pretreated Lenalidomide-Refractory Myeloma Ciltacabtagene autoleucel improved progression-free survival versus two standard triplets Jun 05, 2023
Novel Antibody Induces Durable Responses in Heavily Pretreated Myeloma Overall response rate of 90% in patients who received highest doses of REGN5459 Apr 18, 2023
Novel 'Off the Shelf' CAR-T Product Shows Promise in Myeloma Researchers say safety, efficacy of ALLO-715 comparable to autologous anti-BCMA products Feb 02, 2023
Off-the-Shelf T-Cell Therapy Effective Against Viral Infections After Allo-HCT Produced an antiviral response in 95% of patients with six different types of infection Jan 13, 2023
Talquetamab Offers New Hope in Relapsed/Refractory Multiple Myeloma Bispecific antibody achieves "incredible" response rates over 70% in heavily pretreated patients Dec 11, 2022
Rigid In-Hospital Diet Offers No Advantage in Patients After HSCT "We should eliminate these silly neutropenic diets," expert says Dec 10, 2022
Lenalidomide-Induced Second Cancer Risk Limited to Multiple Myeloma No increased risk to patients with other hematologic malignancies, meta-analysis shows Nov 02, 2022
FDA Broadens Options for Relapsed/Refractory Multiple Myeloma With Teclistamab Bispecific antibody achieved durable responses in a majority of heavily pretreated patients Oct 25, 2022
Anti-BCMA-Based Regimen Impresses in Relapsed/Refractory Myeloma Belamaf plus lenalidomide-dexamethasone achieved encouraging responses Sep 30, 2022
'Unparalleled Times' in Hematology, but Workforce Issues Persist "This is the most exciting time ever" to be a hematologist, says ASH President Jane Winter, MD Sep 26, 2022 video
What's on Tap at the Society of Hematologic Oncology's 10th Annual Meeting Emphasis on novel biological approaches in treating patients with hematologic malignancies Sep 26, 2022
Bispecific Antibody Active in Heavily Treated Multiple Myeloma Responses in 60% of patients who had received a median of five prior lines of therapy Aug 30, 2022
Studies Reinforce Prognostic Role for Circulating Tumor Cells in Myeloma At higher levels, different cutoffs show at least a doubling of PFS, OS hazard ratios Jun 13, 2022
Myeloma Trial Supports 'Personalized Approach' to Upfront Transplant DETERMINATION confirms benefit in triple-therapy setting, but suggests timing can be tailored Jun 06, 2022
Unprecedented PFS Improvement in Relapsed Multiple Myeloma Three-year median with addition of isatuximab to proteasome inhibitor backbone May 26, 2022
Elotuzumab Combination Disappoints in Newly Diagnosed Myeloma Study failed to replicate positive results seen in relapsed/refractory setting May 11, 2022
Allo-Transplant With Omidubicel Hints at Longer-Term Benefits Too "Viable" option for patients eligible for umbilical cord blood transplantation, investigator says Apr 27, 2022
Myeloma at Younger Age Shortens Lifespan Despite Lengthy Overall Survival Disease characteristics, prognostic factors similar to those of older patients Jan 04, 2022
Induction Isatuximab-RVd Combo Boosts MRD Negativity in Multiple Myeloma Half of newly diagnosed, transplant-eligible patients reached minimal residual disease negativity Dec 12, 2021
